Bank of New York Mellon
MNPR icon

Bank of New York Mellon’s Monopar Therapeutics MNPR Stock Holding History

Bank of New York Mellon’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.12M Sell
76,942
-1,676
-2% -$104K ﹤0.01% 2223
2026
Q1 		$4.31M Buy
78,618
+13,761
+21% +$831K ﹤0.01% 2399
2025
Q4 		$4.24M Buy
64,857
+47,687
+278% +$3.9M ﹤0.01% 2413
2025
Q3 		$1.4M Buy
17,170
+8,222
+92% +$368K ﹤0.01% 3009
2025
Q2 		$320K Buy
+8,948
New +$325K ﹤0.01% 3761

Other funds holding MNPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
GL
Gerber LLC Columbus, Ohio $213M AUM 25.63% 1-Year Est. Return
State Board of Administration of Florida Retirement System
State Board of Administration of Florida Retirement System Tallahassee, Florida $60.3B AUM 42.74% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
MIM
Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return

Bank of New York Mellon's MNPR Position: Q2 2026 in Review

Bank of New York Mellon reduced its Monopar Therapeutics (MNPR) stake by 2.1% in Q2 2026, selling an estimated $104K and leaving 76,942 shares worth $7.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2223.

Bank of New York Mellon first reported a position in MNPR in Q2 2025 and has held it in 5 quarters since. 21 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Bank of New York Mellon held 76,942 shares of Monopar Therapeutics worth $7.12M as of Q2 2026.
  • Bank of New York Mellon sold 1,676 Monopar Therapeutics shares in Q2 2026, an estimated $104K.
  • Monopar Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2223 holding.
  • Bank of New York Mellon first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 21 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.